{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-016364","form_type":"8-K","ticker":"RVPH","cik":"0001742927","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.849042+00:00","generated_at":"2026-06-02T01:00:49.875621+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Reviva Q1 net loss $7.4M; FDA alignment on brilaroxazine NDA path","bullets":["Net loss approximately $7.4M ($0.25 per share) for Q1 2024 vs $6.9M ($0.31 per share) for Q1 2023.","Cash $12.0M as of March 31, 2024, down from $23.4M at December 31, 2023.","FDA aligned on registrational Phase 3 program for brilaroxazine in schizophrenia; RECOVER-2 trial start expected Q2 2024.","Topline data from 1-year OLE trial expected Q4 2024; potential NDA submission targeted for Q4 2025.","Company initiated Phase 3 RECOVER-1 data presentations at SIRS and ASCPT meetings in Q1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-016364","json":"https://secwatch.observer/filing/0001437749-24-016364.json","markdown":"https://secwatch.observer/filing/0001437749-24-016364.md","text":"https://secwatch.observer/filing/0001437749-24-016364.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1742927/000143774924016364/0001437749-24-016364-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1742927/000143774924016364/rvph20240510_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T01:00:49.875621+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"522c62980cd45c6fb257130c0905f37750e997ce","claim":"REVIVA PHARMACEUTICALS HOLDINGS, INC. reported first quarter ended March 31, 2024 results: net income approximately $7.4 million, EPS $0.25 per share.","evidence_excerpt":"The Company reported a net loss of approximately $7.4 million, or $0.25 per share, for the three months ended March 31, 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774924016364/0001437749-24-016364-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Net income","value":"approximately $7.4 million"},{"label":"EPS","value":"$0.25 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}